Currently, although there are many emerging therapies for HER2-positive breast cancer, including TKIs, ADCs, and bispecific antibodies, trastuzumab is still irreplaceable in the treatment of HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.